AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
· Favourable safety profile in marked contrast to traditional inotropic therapeutics · AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a

Free information resources make it easier to enter the field of Sustainable Chemistry and drive sustainable innovationWhat defines Sustainable Chemistry? How can companies, start-ups, and public institutions systematically integrate sustainability into innovations, products, and processes? And where can stakeholders from industry, science, and policymaking find reliable information and practical guidance? The International Sustainable Chemistry Collaborative Centre (ISC3) addresses these questions with a new, comprehensive, and free set of resources. The simplified 10